Financing ·
China SXT Pharmaceuticals, Inc. entered into an amendment to its Securities Purchase Agreement with institutional…
SXTCChina SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc. entered into an amendment to its Securities Purchase Agreement with institutional investors on August 27, 2026. The company previously executed a 1-for-80 share consolidation effective August 10, 2026, which adjusted the floor price for pre-paid purchases from $0.20 to $16.00 per share. The amendment reduced this floor price back to $0.20 per share while maintaining an aggregate principal amount of up to $31,500,000. This transaction involves the issuance and sale of Class A ordinary shares. China SXT Pharmaceuticals operates in the pharmaceutical industry, focusing on the research, development, and manufacturing of drugs.